Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
A new Phase 1 study looking at psilocybin in combination with psychological support as a treatment for females with anorexia nervosa has shown positive results.
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
Alcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use...
MGC Pharmaceuticals has received permission to import psilocybin into Slovenia.
Kernel has published results from its Cybin-sponsored neuroimaging study which show the ability of Kernel’s Flow1 system to capture and analyse brain changes induced by psychedelics.
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
As their 300-gram MDMA shipment got to the border, PharmAla Biotech found themselves in a sticky situation.
The Psychedelic Access and Research Alliance (PAREA) has released a position statement calling on the EU to harness psychedelics in a bid to create innovation in...